Companies / Iovance Biotherapeutics, Inc. / Activity
Activity — Iovance Biotherapeutics, Inc.
12 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Marshall Wace, LLP 13F manager | New | Common stock | $8.27M | +2.4M | 2,355,612 0.52% of shares | medium |
| Q4 2025 as of | Corsair Capital Management, L.P. 13F manager | New | Common stock | $819.0K | +300K | 300,000 0.07% of shares | low |
| Q1 2026 as of | Mariner, LLC 13F manager | New | Common stock | $401.1K | +114K | 114,292 0.03% of shares | low |
| Q2 2026 as of | WINTON GROUP Ltd 13F manager | New | Common stock | $192.2K | +46K | 46,200 0.01% of shares | low |
| Q2 2025 as of | Leonteq Securities AG 13F manager | New | Common stock | $163.4K | +95K | 95,000 0.02% of shares | low |
| Q2 2025 as of | Sanctuary Advisors, LLC 13F manager | New | Common stock | $59.7K | +35K | 34,707 <0.01% of shares | low |
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | Common stock | $56.4K | +26K | 26,000 <0.01% of shares | low |
| Q2 2026 as of | Wealthfront Advisers LLC 13F manager | New | Common stock | $53.9K | +13K | 12,959 <0.01% of shares | low |
| Q1 2026 as of | Curi Capital, LLC 13F manager | New | Common stock | $42.4K | +12K | 12,092 <0.01% of shares | low |
| Q2 2025 as of | Pine Valley Investments Ltd Liability Co 13F manager | New | Common stock | $31.5K | +18K | 18,338 <0.01% of shares | low |
| Q1 2026 as of | Natixis 13F manager | New | Common stock | $26.3K | +8K | 7,503 <0.01% of shares | low |
| Q1 2026 as of | Hantz Financial Services, Inc. 13F manager | New | Common stock | $47 | +14K | 13,513 <0.01% of shares | low |